| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers M > Headlines for Migenix Inc. > News item |
Migenix, Cutanea sign licensing deal to develop, commercialize skin drug MX-594AN
By E. Janene Geiss
Philadelphia, Dec. 8 - Migenix Inc. and Cutanea Life Sciences, Inc. said Thursday that they have entered into a license agreement to develop and commercialize MX-594AN for a number of dermatological indications. The compound is currently in clinical development for the treatment of mild to moderate acne vulgaris.
Under the terms of the agreement, Migenix will receive a small, up-front payment and up to $21 million in development and commercialization milestone payments, as well as royalties on net sales, according to a company news release.
Cutanea will have exclusive worldwide rights to develop and market MX-594AN and its analogs, officials said. Future development activities will focus on the treatment of dermatological conditions with inflammatory and infectious etiologies.
Cutanea will take full responsibility for funding all development activities including all formulation, clinical, regulatory and commercialization costs, officials said.
"MX-594AN is a compound with unique characteristics, including multiple modes of action. We are excited to include this molecule in our development portfolio and we are anxious to commence its development across a number of target conditions," Robert Bitterman, president and chief executive officer of Cutanea, said in the release.
MX-594AN is an antimicrobial cationic peptide in development as a topical prescription treatment for mild to moderate acne vulgaris. It has completed five clinical trials in the United States - three phase 1 studies and two phase 2 studies. The phase 2 trials demonstrated evidence of efficacy against all acne lesion types, officials said.
Cutanea is a Philadelphia pharmaceutical company focused on development of dermatological therapies.
Migenix is a Vancouver, B.C., clinical-stage developer of drugs for infectious and degenerative diseases.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.